Clinical Trials & Research

In a new study led by Yale Cancer Center, researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier (BBB) and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody. The study was published today online in the Journal of Clinical Investigation Insight. “These findings are very
0 Comments
Successfully arresting the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ’ the causative pathogen of coronavirus disease 2019 (COVID-19) ’ requires global vaccination. While high-income countries have already begun vaccinating their citizens, developing and lower-income countries are not expected to ramp up their vaccination programs until next year ’ increasing the risk for
0 Comments
A team of scientists from the Columbia University, New York, has recently identified a potential biomarker to predict acute kidney injury in coronavirus disease 2019 (COVID-19) patients. By analyzing urine samples of 444 COVID-19 patients, they have revealed that the urinary level of neutrophil gelatinase-associated lipocalin (NGAL) can be used to determine the severity and
0 Comments
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, has claimed over 3.8 million lives worldwide. A ray of hope became visible as vaccines received emergency use authorizations (EUAs). Simultaneously, however, new variants of the virus have emerged, some forming variants of concern (VOCs) that are either more
0 Comments
The coronavirus disease 2019 (COVID-19) pandemic ’ caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ’ was declared in March 2020, two months after the initial recognition of novel pneumonia-like symptoms in a group of patients in Wuhan, China. Since then, it has spread to over 192 countries and territories, causing well
0 Comments
COVID-19 vaccine candidate efficacy in those 18 to <65 years old was preserved in influenza vaccine recipients Influenza vaccine immunogenicity preserved Study demonstrated no early safety concerns Data available ahead of publication via preprint server, medRxiv  GAITHERSBURG, Md., June 14, 2021 /PRNewswire/ – Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced
0 Comments
93% efficacy against predominantly circulating Variants of Concern and Variants of Interest 91% efficacy in high-risk populations 100% efficacy against variants “not considered Variants of Concern/Interest” All COVID-19 hospitalizations/death occurred in the placebo group Company to host investor conference call today at 8:30 am ET GAITHERSBURG, Md., June 14, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq:
0 Comments
93% efficacy against predominantly circulating Variants of Concern and Variants of Interest 91% efficacy in high-risk populations 100% efficacy against variants “not considered Variants of Concern/Interest” All COVID-19 hospitalizations/death occurred in the placebo group Company to host investor conference call today at 8:30 am ET GAITHERSBURG, Md., June 14, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq:
0 Comments
The vaccination program has commenced in many countries worldwide, which is marked as a significant milestone in curbing the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causal agent of the coronavirus disease 2019 (COVID-19) pandemic. These vaccines, which have received emergency authorization from different regulatory bodies around the world, such as the
0 Comments